undamentalytics Newsletter
Sign in

Thermo Fisher Scientific cash flow statement

In fiscal 2025, Thermo Fisher Scientific's operations generated $7.82bn of cash; it spent $1.52bn on capital projects, leaving free cash flow of $6.29bn. It returned $636m in dividends and $3.00bn through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations1,6591,4981,6912,0402,0112,6202,9423,2584,0054,5434,9738,2899,3129,1548,4068,6677,8189,324
Depreciation and amortisation7637408609841,0001,6851,6881,7582,0332,2675646588319861,0681,1561,0501,236
Stock-based pay6782807891117125133159181181196230307278301310344
Capital spending2002452613152824284234445087589261,4742,5232,2431,4791,4001,5251,728
Free cash flow1,4591,2521,4301,7241,7282,1922,5192,8143,4973,7854,0476,8156,7896,9116,9277,2676,2937,596
Free cash flow after stock pay1,3921,1711,3501,6461,6372,0752,3942,6813,3383,6043,8666,6196,5596,6046,6496,9665,9837,252
Dividends paid——0142216235241238237266297337395455523583636673
Share buybacks4151,0131,3381,1509005001,2507505001,5001,5002,0003,0003,0004,0003,0004,037
Shares issued5477158002,942001,69000———————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DHR vs TMOIQV vs TMOICLR vs TMO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Thermo Fisher Scientific's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Thermo Fisher Scientific.